- Home
- GTE vs MRSN Comparison
GTE vs MRSN Comparison
Compare GTE & MRSN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GTE
- MRSN
- Stock Information
- Founded
- GTE 2003
- MRSN 2001
- Country
- GTE Canada
- MRSN United States
- Employees
- GTE N/A
- MRSN N/A
- Industry
- GTE Oil & Gas Production
- MRSN Biotechnology: Pharmaceutical Preparations
- Sector
- GTE Energy
- MRSN Health Care
- Exchange
- GTE Nasdaq
- MRSN Nasdaq
- Market Cap
- GTE 232.6M
- MRSN 230.0M
- IPO Year
- GTE N/A
- MRSN 2017
- Fundamental
- Price
- GTE $6.09
- MRSN $2.21
- Analyst Decision
- GTE Hold
- MRSN Buy
- Analyst Count
- GTE 1
- MRSN 6
- Target Price
- GTE $10.00
- MRSN $6.00
- AVG Volume (30 Days)
- GTE 260.5K
- MRSN 1.1M
- Earning Date
- GTE 11-04-2024
- MRSN 11-13-2024
- Dividend Yield
- GTE N/A
- MRSN N/A
- EPS Growth
- GTE 157.68
- MRSN N/A
- EPS
- GTE 1.43
- MRSN N/A
- Revenue
- GTE $629,503,000.00
- MRSN $34,837,000.00
- Revenue This Year
- GTE $3.70
- MRSN N/A
- Revenue Next Year
- GTE $23.85
- MRSN $7.15
- P/E Ratio
- GTE $4.28
- MRSN N/A
- Revenue Growth
- GTE N/A
- MRSN N/A
- 52 Week Low
- GTE $4.72
- MRSN $1.22
- 52 Week High
- GTE $10.40
- MRSN $6.28
- Technical
- Relative Strength Index (RSI)
- GTE 42.53
- MRSN 51.26
- Support Level
- GTE $5.95
- MRSN $2.12
- Resistance Level
- GTE $6.84
- MRSN $2.83
- Average True Range (ATR)
- GTE 0.31
- MRSN 0.24
- MACD
- GTE -0.02
- MRSN 0.03
- Stochastic Oscillator
- GTE 12.98
- MRSN 39.81
About GTE Gran Tierra Energy Inc.
Gran Tierra Energy Inc is an independent energy company. It is engaged in the acquisition, exploration, development, and production of oil and gas properties. The firm produces light crude oil, supplemented with medium crude and natural gas. Gran Tierra holds interests in producing and prospective properties in Colombia and prospective properties in Ecuador. The company derives its revenue from Colombia.
About MRSN Mersana Therapeutics Inc.
Mersana Therapeutics Inc is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to develop targeted drugs with increased tolerability and expanded opportunities to deliver meaningful clinical benefits to patients. The Company's early stage programs includes XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING agonist ADC developed using the Company's Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2. The Company also has two earlier stage preclinical candidates, XMT-2068 and XMT-2175, both of which leverage the Company's Immunosynthen platform and target tumor-associated antigens.